ABCSG 39/Aphinity Summary

Randomized, multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo vs. chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer.

Start:  
Coordinating investigator: Steger, Günther; Vienna
Sample size:  

Design:
(Click to enlarge)

ABCSG-39 Design

Link for studyteam-members only

Further information about this trial

Access to these informations only with keyword. If required, please ask the responsible project manager.